Cure My Disease

Don't miss your cure!

 Log in / Sign up

New urine test aims to catch aggressive prostate cancer early

NCT ID NCT07526545

Not yet recruiting Diagnosis Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test a new urine test called My Prostate Score 2 (MPS2) combined with MRI to detect aggressive prostate cancer in men aged 50-75 with elevated PSA levels. The goal is to find only the cancers that need treatment and avoid unnecessary biopsies. The trial plans to enroll 800 participants and compare the new approach to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
My Prostate Score 2 (MPS2) urine test
What this could lead to
If successful, this approach could improve early detection of aggressive prostate cancer while reducing unnecessary biopsies and MRIs.
What could go wrong
The trial hasn't started yet, and the urine test is still investigational. It may not prove better than current methods, and results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.